#PAVmed

Thiard News@F4F

@newsen.bsky.social

1 month ago

PAVmed Strengthens Financial Position by Closing Preferred Stock and Note Financings Successfully PAVmed Inc. announces the successful closure of preferred stock and senior secured note financings, effectively eliminating previous convertible securities and strengthening its balance sheet remarkably.

PAVmed Strengthens Financial Position by Closing Preferred Stock and Note Financings Successfully #USA #New_York #EsoGuard #PAVmed #Veris_Health

Thiard News@F4F

@newsen.bsky.social

2 months ago

PAVmed Completes Reverse Stock Split to Maintain Nasdaq Listing Compliance PAVmed Inc. announces a 1-for-30 reverse stock split that goes into effect on January 2, 2026, enhancing compliance with Nasdaq's listing requirements.

PAVmed Completes Reverse Stock Split to Maintain Nasdaq Listing Compliance #USA #New_York #NASDAQ #Stock_Split #PAVmed

Thiard News@F4F

@newsen.bsky.social

4 months ago

Lucid Diagnostics Set to Engage Investors at MedTech Forum in NYC Lucid Diagnostics will participate in the upcoming Canaccord Genuity MedTech Forum, emphasizing its cancer prevention endeavors and investor engagements.

Lucid Diagnostics Set to Engage Investors at MedTech Forum in NYC #USA #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

4 months ago

PAVmed's Business Update for Q3 2025 Highlights Strategic Developments PAVmed Inc. shares business updates for Q3 2025, confirming strong financial results and innovative technological advancements in medical technology.

PAVmed's Business Update for Q3 2025 Highlights Strategic Developments #USA #New_York #Lucid_Diagnostics #PAVmed #Veris_Health

Thiard News@F4F

@newsen.bsky.social

4 months ago

Lucid Diagnostics Reports Strong Financials and Business Updates for Q3 2025 In Q3 2025, Lucid Diagnostics processed nearly 3,000 EsoGuard tests, raising $1.2 million in revenue with positive Medicare coverage developments.

Lucid Diagnostics Reports Strong Financials and Business Updates for Q3 2025 #USA #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

5 months ago

PAVmed and Ohio State University's Strategic Partnership Enhances Cancer Care PAVmed Inc.'s partnership with Ohio State University enhances personalized cancer care with the Veris Cancer Care Platform, empowering patients and providers alike.

PAVmed and Ohio State University's Strategic Partnership Enhances Cancer Care #USA #Columbus #PAVmed #Veris_Health #OSUCCC

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lucid Diagnostics to Host Important Investor Call on September 8, 2025, to Discuss Recent Developments On September 8, 2025, Lucid Diagnostics will conduct an investor call to discuss critical outcomes from a recent advisory meeting regarding their cancer detection technology.

Lucid Diagnostics to Host Important Investor Call on September 8, 2025, to Discuss Recent Developments #United_States #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

6 months ago

PAVmed Partners with Duke University to Revolutionize Esophageal Imaging Technology PAVmed has signed a letter of intent with Duke University to license advanced imaging technology that improves diagnosis and treatment of esophageal precancer.

PAVmed Partners with Duke University to Revolutionize Esophageal Imaging Technology #USA #New_York #PAVmed #Duke_University #esophageal_technology

Thiard News@F4F

@newsen.bsky.social

7 months ago

PAVmed Updates Investors with Q2 2025 Financial Results and Business Developments PAVmed, a medical technology company, presents its second quarter 2025 financial results and essential business updates, showcasing growth and future strategies.

PAVmed Updates Investors with Q2 2025 Financial Results and Business Developments #United_States #New_York #Lucid_Diagnostics #PAVmed #Veris_Health

Thiard News@F4F

@newsen.bsky.social

7 months ago

PAVmed Secures 180-Day Extension from Nasdaq to Meet Minimum Bid Price Requirement PAVmed Inc. announced it has been granted a 180-day extension by Nasdaq to comply with minimum bid price rules, giving them until January 2026 to meet requirements.

PAVmed Secures 180-Day Extension from Nasdaq to Meet Minimum Bid Price Requirement #United_States #New_York #NASDAQ #Lucid_Diagnostics #PAVmed

Thiard News@F4F

@newsen.bsky.social

8 months ago

PAVmed's Subsidiary Veris Health Raises $2.5 Million in Equity Financing for Innovations PAVmed's subsidiary, Veris Health, successfully completed a $2.5 million equity financing to advance its innovative cancer care solutions, showcasing investor confidence.

PAVmed's Subsidiary Veris Health Raises $2.5 Million in Equity Financing for Innovations #USA #New_York #Cancer_Care #PAVmed #Veris_Health

Thiard News@F4F

@newsen.bsky.social

9 months ago

PAVmed's Veris Health Partners with Ohio State University for Cancer Care Advancement PAVmed Inc.'s subsidiary Veris Health has entered a strategic partnership with The Ohio State University Comprehensive Cancer Center to enhance cancer patient care through innovative technology.

PAVmed's Veris Health Partners with Ohio State University for Cancer Care Advancement #United_States #Columbus #Cancer_Care #PAVmed #Veris_Health

Thiard News@F4F

@newsen.bsky.social

9 months ago

Lucid Diagnostics to Join Russell Indexes—A Milestone for Cancer Detection Innovation Lucid Diagnostics has announced its addition to the Russell 2000 and Russell 3000 Indexes. This significant achievement signals growth in cancer detection innovation and potential investment opportunities.

Lucid Diagnostics to Join Russell Indexes—A Milestone for Cancer Detection Innovation #United_States #New_York #Lucid_Diagnostics #Esophageal_Cancer #PAVmed

Thiard News@F4F

@newsen.bsky.social

10 months ago

PAVmed Reports First Quarter 2025 Financials and Business Progress PAVmed has provided its business update and financial results for Q1 2025, showcasing progress in diagnostics and plans for biopharma expansion.

PAVmed Reports First Quarter 2025 Financials and Business Progress #USA #New_York #Lucid_Diagnostics #PAVmed #Veris_Health

Thiard News@F4F

@newsen.bsky.social

10 months ago

Lucid Diagnostics Reports First Quarter 2025 Progress and Financial Highlights Lucid Diagnostics shares significant financial results and business progress for Q1 2025, highlighting advances in cancer prevention diagnostics and upcoming milestones.

Lucid Diagnostics Reports First Quarter 2025 Progress and Financial Highlights #USA #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

1 year ago

Lucid Diagnostics Completes $15.3 Million Direct Stock Offering to Boost Operations Lucid Diagnostics has successfully closed a $15.3 million direct stock offering, aiming to enhance working capital and support corporate needs.

Lucid Diagnostics Completes $15.3 Million Direct Stock Offering to Boost Operations #United_States #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

1 year ago

Lucid Diagnostics Announces Significant $15.3 Million Direct Stock Offering to Boost Cancer Prevention Initiatives Lucid Diagnostics has declared a direct stock offering worth $15.3 million, aiming to enhance its cancer prevention technologies and operations.

Lucid Diagnostics Announces Significant $15.3 Million Direct Stock Offering to Boost Cancer Prevention Initiatives #United_States #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

1 year ago

PAVmed Inc. Successfully Completes $2.37 Million Private Placement Financing for Cancer Care Innovations PAVmed Inc. announces successful completion of $2.37 million private placement financing to advance its Veris Health subsidiary for improved cancer patient care.

PAVmed Inc. Successfully Completes $2.37 Million Private Placement Financing for Cancer Care Innovations #United_States #New_York #Private_Placement #PAVmed #Veris_Health

Thiard News@F4F

@newsen.bsky.social

1 year ago

PAVmed Successfully Meets Nasdaq's Stockholders' Equity Requirements After Strategic Changes PAVmed Inc. recently announced that it has regained compliance with Nasdaq's stockholders' equity requirement, thanks to strategic initiatives enhancing its equity base.

PAVmed Successfully Meets Nasdaq's Stockholders' Equity Requirements After Strategic Changes #USA #New_York #NASDAQ #Lucid_Diagnostics #PAVmed